TBPH vs. ANNX, PLRX, AKRO, KNSA, SDGR, ARDX, TARO, EWTX, LGND, and MORF Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Annexon (ANNX), Pliant Therapeutics (PLRX), Akero Therapeutics (AKRO), Kiniksa Pharmaceuticals (KNSA), Schrödinger (SDGR), Ardelyx (ARDX), Taro Pharmaceutical Industries (TARO), Edgewise Therapeutics (EWTX), Ligand Pharmaceuticals (LGND), and Morphic (MORF). These companies are all part of the "pharmaceutical preparations" industry.
Theravance Biopharma (NASDAQ:TBPH ) and Annexon (NASDAQ:ANNX ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings.
Theravance Biopharma presently has a consensus price target of $20.50, indicating a potential upside of 137.82%. Annexon has a consensus price target of $15.33, indicating a potential upside of 217.46%. Given Annexon's higher possible upside, analysts clearly believe Annexon is more favorable than Theravance Biopharma.
In the previous week, Theravance Biopharma had 6 more articles in the media than Annexon. MarketBeat recorded 9 mentions for Theravance Biopharma and 3 mentions for Annexon. Annexon's average media sentiment score of 0.71 beat Theravance Biopharma's score of 0.09 indicating that Annexon is being referred to more favorably in the news media.
Annexon has a net margin of 0.00% compared to Theravance Biopharma's net margin of -72.79%. Theravance Biopharma's return on equity of -18.97% beat Annexon's return on equity.
99.1% of Theravance Biopharma shares are owned by institutional investors. 6.9% of Theravance Biopharma shares are owned by company insiders. Comparatively, 12.7% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Theravance Biopharma has higher revenue and earnings than Annexon. Theravance Biopharma is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Theravance Biopharma received 293 more outperform votes than Annexon when rated by MarketBeat users. However, 73.33% of users gave Annexon an outperform vote while only 63.47% of users gave Theravance Biopharma an outperform vote.
Theravance Biopharma has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.
Summary Theravance Biopharma and Annexon tied by winning 8 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Theravance Biopharma Competitors List
Related Companies and Tools
